Portzamparc Groupe BNP Paribas is proud to have supported ONWARD Medical (https://ir.onwd.com), a Dutch company specialized in neurotechnology designed to restore movement, function and independence in people with spinal cord injury and other movement disorders, in its primary Accelerated Bookbuilding (ABB) capital increase of over €50 million.
Portzamparc Groupe BNP Paribas acted as Joint Bookrunner for the private placement.
👉 Details of the transaction:
Largest follow-on among publicly listed MedTech companies in Europe this year.
Strong demand from existing shareholders and new Tier 1, long-only, and sector specialist investors.
Anchor investors included Ottobock, Invus, and ASR Global Impact Equity Fund managed by a.s.r. Asset Management N.V.
Pricing set at €4.50 per share, representing a 12.5% discount vs. Wednesday’s closing price (€5.14).
The proceeds will support ONWARD Medical’s commercial expansion of ARC-EX® and the advancement of its pipeline, including the planned pivotal study for its implantable ARC-IM® system.
